CYP3A5*3 polymorphism and its clinical implications and pharmacokinetic role

Ji-Young Park, Yu Jung Cha, Kyoung Ah Kim

Research output: Contribution to journalArticle

Abstract

The cytochrome P450 (CYP) 3A subfamily is estimated to participate in the biotransformation of 50% of the currently prescribed drugs. Four members of the CYP3A subfamily have been identified in humans: CYP3A4, CYP3A5, CYP3A7, and CYP3A43. Initial data suggested that CYP3A5 accounts for only a small proportion of the total hepatic CYP3A in about 20% of samples, but it was later revealed that CYP3A5 represents more than 50% of the total CYP3A amount in some individuals. Several genetic variants have been described for the CYP3A5 gene, of which the CYP3A5*3 allele (gA6986G), the most common form and leading to the loss of CYP3A5 activity, has been extensively investigated in the aspect of pharmacokinetics and disease risk. This review summarized the molecular characteristics of the CYP3A5 gene, and discusses the association of the CYP3A5*3 polymorphism with disease risks such as cancer and hypertension, along with its role in the pharmacokinetics of CYP3A substrates.

Original languageEnglish
Article numberA002
Pages (from-to)3-7
Number of pages5
JournalTranslational and Clinical Pharmacology
Volume22
Issue number1
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Cytochrome P-450 CYP3A
Pharmacokinetics
Biotransformation
Genes

Keywords

  • Cancer
  • CYP3A5*3
  • Cytochrome
  • P450
  • Pharmacogenetics
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

CYP3A5*3 polymorphism and its clinical implications and pharmacokinetic role. / Park, Ji-Young; Cha, Yu Jung; Kim, Kyoung Ah.

In: Translational and Clinical Pharmacology, Vol. 22, No. 1, A002, 01.01.2014, p. 3-7.

Research output: Contribution to journalArticle

@article{cbb9f6256bf94dce8fb3531890cff4f1,
title = "CYP3A5*3 polymorphism and its clinical implications and pharmacokinetic role",
abstract = "The cytochrome P450 (CYP) 3A subfamily is estimated to participate in the biotransformation of 50{\%} of the currently prescribed drugs. Four members of the CYP3A subfamily have been identified in humans: CYP3A4, CYP3A5, CYP3A7, and CYP3A43. Initial data suggested that CYP3A5 accounts for only a small proportion of the total hepatic CYP3A in about 20{\%} of samples, but it was later revealed that CYP3A5 represents more than 50{\%} of the total CYP3A amount in some individuals. Several genetic variants have been described for the CYP3A5 gene, of which the CYP3A5*3 allele (gA6986G), the most common form and leading to the loss of CYP3A5 activity, has been extensively investigated in the aspect of pharmacokinetics and disease risk. This review summarized the molecular characteristics of the CYP3A5 gene, and discusses the association of the CYP3A5*3 polymorphism with disease risks such as cancer and hypertension, along with its role in the pharmacokinetics of CYP3A substrates.",
keywords = "Cancer, CYP3A5*3, Cytochrome, P450, Pharmacogenetics, Pharmacokinetics",
author = "Ji-Young Park and Cha, {Yu Jung} and Kim, {Kyoung Ah}",
year = "2014",
month = "1",
day = "1",
doi = "10.12793/tcp.2014.22.1.3",
language = "English",
volume = "22",
pages = "3--7",
journal = "Translational and Clinical Pharmacology",
issn = "2289-0882",
publisher = "Korean Society for Clinical Pharmacology and Therapeutics",
number = "1",

}

TY - JOUR

T1 - CYP3A5*3 polymorphism and its clinical implications and pharmacokinetic role

AU - Park, Ji-Young

AU - Cha, Yu Jung

AU - Kim, Kyoung Ah

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The cytochrome P450 (CYP) 3A subfamily is estimated to participate in the biotransformation of 50% of the currently prescribed drugs. Four members of the CYP3A subfamily have been identified in humans: CYP3A4, CYP3A5, CYP3A7, and CYP3A43. Initial data suggested that CYP3A5 accounts for only a small proportion of the total hepatic CYP3A in about 20% of samples, but it was later revealed that CYP3A5 represents more than 50% of the total CYP3A amount in some individuals. Several genetic variants have been described for the CYP3A5 gene, of which the CYP3A5*3 allele (gA6986G), the most common form and leading to the loss of CYP3A5 activity, has been extensively investigated in the aspect of pharmacokinetics and disease risk. This review summarized the molecular characteristics of the CYP3A5 gene, and discusses the association of the CYP3A5*3 polymorphism with disease risks such as cancer and hypertension, along with its role in the pharmacokinetics of CYP3A substrates.

AB - The cytochrome P450 (CYP) 3A subfamily is estimated to participate in the biotransformation of 50% of the currently prescribed drugs. Four members of the CYP3A subfamily have been identified in humans: CYP3A4, CYP3A5, CYP3A7, and CYP3A43. Initial data suggested that CYP3A5 accounts for only a small proportion of the total hepatic CYP3A in about 20% of samples, but it was later revealed that CYP3A5 represents more than 50% of the total CYP3A amount in some individuals. Several genetic variants have been described for the CYP3A5 gene, of which the CYP3A5*3 allele (gA6986G), the most common form and leading to the loss of CYP3A5 activity, has been extensively investigated in the aspect of pharmacokinetics and disease risk. This review summarized the molecular characteristics of the CYP3A5 gene, and discusses the association of the CYP3A5*3 polymorphism with disease risks such as cancer and hypertension, along with its role in the pharmacokinetics of CYP3A substrates.

KW - Cancer

KW - CYP3A53

KW - Cytochrome

KW - P450

KW - Pharmacogenetics

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84943139321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943139321&partnerID=8YFLogxK

U2 - 10.12793/tcp.2014.22.1.3

DO - 10.12793/tcp.2014.22.1.3

M3 - Article

AN - SCOPUS:84943139321

VL - 22

SP - 3

EP - 7

JO - Translational and Clinical Pharmacology

JF - Translational and Clinical Pharmacology

SN - 2289-0882

IS - 1

M1 - A002

ER -